Ovid Therapeutics Inc. (OVID)

Name: Ovid Therapeutics Inc. (OVID) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Ovid Therapeutics Inc. (OVID)

Stock Card

$2.80

$0.02 (0.54%)

As on 04-Sep-2026 13:38EDT

Market cap

$547 Mln

Revenue (TTM)

$2 Mln

P/E Ratio

P/B Ratio

2.7

Div. Yield

0 %

Ovid Therapeutics (OVID) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 2.71 High: 2.81

52 Week Range

Low: 1.12 High: 3.11

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.3 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-0.7
Debt to Equity

0
Book Value

$--
EPS

$-0.5
Face value

--
Shares outstanding

195,297,857

10 Years Aggregate

CFO

$-185.65 Mln

EBITDA

$-283.06 Mln

Net Profit

$-273.71 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Ovid Therapeutics (OVID)	71.5	20.0	16.9	110.2	-7.6	-4.5	--
BSE Sensex	-9.6	-2.7	2.9	-5.0	5.4	5.7	10.4
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 04-Sep-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022	2021	2020	2019
Ovid Therapeutics (OVID)	74.6	-70.7	73.1	-42.1	39.0	-44.3	71.5
S&P Small-Cap 600	4.0	7.0	13.9	-17.4	25.3	9.6	20.9
BSE Sensex	9.1	8.1	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Ovid Therapeutics (OVID)	2.8	546.8	1.6	-34.5	-2,257.7	-20.3	--	2.7
Arrowhead Pharmaceuticals (ARWR)	84.8	11,993.9	669.5	-320.0	-0.8	-71.1	--	26.9
Ascendis Pharma A/S - ADR	268.4	16,261.1	1,054.4	755.9	5.7	--	19	9.8
Cytokinetics Inc (CYTK)	72.4	10,022.2	71.0	-894.0	-1,175.8	--	--	60.3
Exelixis (EXEL)	59.0	13,491.7	2,435.9	860.6	31.0	43	17.4	7.4
Halozyme Therapeutics (HALO)	110.2	11,957.0	1,663.7	413.6	36.3	430	30.9	84.5
Krystal Biotech (KRYS)	355.5	10,402.8	440.5	241.5	33.4	18.7	44.1	7.8
Kymera Therapeutics (KYMR)	118.2	9,718.7	105.0	-299.7	-227.2	-19.4	--	6.6
Madrigal Pharmaceuticals (MDGL)	541.4	12,332.1	1,283.9	-325.1	-19.0	-57.7	--	24.0
Medpace Holdings (MEDP)	592.0	16,765.1	2,782.3	491.5	21.1	110.1	35.2	39.3

Shareholding Pattern

View Details

About Ovid Therapeutics (OVID)

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a... GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York. Read more

President, CEO & Chairman

Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir
President, CEO & Chairman

Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D.
Headquarters

New York, NY
Website

https://www.ovidrx.com

FAQs for Ovid Therapeutics (OVID)

What is the current share price of Ovid Therapeutics Inc (OVID) Today?

The share price of Ovid Therapeutics Inc (OVID) is $2.80 (NASDAQ) as of 04-Sep-2026 13:38 EDT. Ovid Therapeutics Inc (OVID) has given a return of -7.57% in the last 3 years.

What is the current PB & PE ratio of Ovid Therapeutics Inc (OVID)?

Since, TTM earnings of Ovid Therapeutics Inc (OVID) is negative, P/E ratio is not available.
The P/B ratio of Ovid Therapeutics Inc (OVID) is 2.73 times as on 28-Aug-2026, a 47 discount to its peers’ median range of 5.18 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2025	-7.64	1.02
2024	-2.51	0.97
2023	-4.35	2.59
2022	-2.55	0.99
2021	1.78	1.22

What is the 52 Week High and Low of Ovid Therapeutics Inc (OVID)?

The 52-week high and low of Ovid Therapeutics Inc (OVID) are Rs 3.11 and Rs 1.12 as of 06-Sep-2026.

What is the market cap of Ovid Therapeutics Inc (OVID)?

Ovid Therapeutics Inc (OVID) has a market capitalisation of $ 547 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.

Should I invest in Ovid Therapeutics Inc (OVID)?

Before investing in Ovid Therapeutics Inc (OVID), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.